SCHEMBL3199183

SCHEMBL3199183

COc1cc(OC)cc(C(=O)NC2CCCC(c3nc4cc(C)ccc4[nH]3)C2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
GRM5 P41594 2/20 0.43
CXCR6 O00574 3/20 0.43
MAPT P10636 2/20 0.42
GAA P10253 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HPGDS O60760 2/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
LMNA P02545 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CNR1 P21554 1/20 0.40
KCNH2 Q12809 1/20 0.40
AURKB Q96GD4 1/20 0.40
MCHR1 Q99705 2/20 0.40
ADRA2A P08913 1/20 0.40
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13490307 0.93 NPC1 (0.51) MEN1KMT2AGRM5CXCR6MAPT
SCHEMBL3211354 0.91 MEN1 (0.49) MEN1KMT2AGRM5CXCR6MAPT
SCHEMBL3213873 0.90 GRM5 (0.52) MEN1KMT2AGRM5CXCR6MAPT
SCHEMBL3216538 0.90 MEN1 (0.48) MEN1KMT2AGRM5CXCR6MAPT
SCHEMBL3209813 0.90 MEN1 (0.48) MEN1KMT2AGRM5CXCR6MAPT
SCHEMBL13490329 0.90 GRM5 (0.52) MEN1KMT2AGRM5CXCR6MAPT
SCHEMBL3213601 0.89 KMT2A (0.47) MEN1KMT2AGRM5CXCR6MAPT
SCHEMBL13490618 0.89 MEN1 (0.54) MEN1KMT2AGRM5CXCR6MAPT
SCHEMBL13490741 0.89 MEN1 (0.54) MEN1KMT2AGRM5CXCR6MAPT
SCHEMBL13490372 0.89 MEN1 (0.54) MEN1KMT2AGRM5CXCR6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029615-A1 BENZIMIDAZOLE DERIVATIVES PFIZER INC. 2010-02-04 US disclosed
EP-2121626-A1 BENZIMIDAZOLE DERIVATIVES Pfizer Products Inc. (US) 2009-11-25 EP disclosed
WO-2008075196-A1 BENZIMIDAZOLE DERIVATIVES PFIZER PRODUCTS INC. (US) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029615-A1 BENZIMIDAZOLE DERIVATIVES ACIN1, HAT1, CCNE1 MEN1 2892/4885KMT2A 1782/4885GRM5 4172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.